Overview
Vivani reports Q3 net loss widening to $6.5 mln, with increased operating expenses
Vivani secures $25.7 mln in cash and commitments for development projects
Outlook
Vivani plans Phase 1 study of semaglutide implant in early 2026
Company preparing for Phase 2 study pending Phase 1 results
Vivani expects Cortigent spin-off post-SEC operations resumption
Result Drivers
FUNDING SECURED - Vivani secures $25.7 mln in cash and commitments to support accelerated development of NPM-139
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.11 | ||
Q3 Net Income | -$6.53 mln | ||
Q3 Income from Operations | -$6.73 mln | ||
Q3 Operating Expenses | $6.73 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vivani Medical Inc is $4.00, about 61.7% above its November 12 closing price of $1.53
Press Release: ID:nGNXHJLcl
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)